Five year changes in mental health and associations with vitamin B12/folate status of elderly Europeans.

What Was Tested

Researchers studied Cyanocobalamin (Vitamin B12) in this clinical trial publication.

Who Took Part

The study group was 1099 subjects.

The age groups tagged for this paper are older adults and people over 80, both men and women.

Of the 1099 enrolled subjects in the Follow-up study, 586 participated in the Finale study.

Mental health status was assessed by the Mini-Mental State Examination (MMSE, cognitive impairment defined as MMSE<23) and the 15-item Geriatric Depression Scale (GDS, depression defined as GDS>5).

How the Study Was Run

The design is described as multicenter.

Running at several centres spread the Cyanocobalamin (Vitamin B12) study over different clinics and patient groups.

A longitudinal, multicentre study including a Baseline study, a Follow-up study, and a Finale study.

Inhabitants of 11 European towns, born between 1913 and 1918, were randomly selected at baseline to participate in the SENECA study.

What Was Measured

The subject headings attached to it are Aging, Europe, Folic Acid, Longitudinal Studies, Mental Health, Nutrition Surveys and Psychiatric Status Rating Scales.

What This Means in Plain Language

The paper is a multicenter study of Cyanocobalamin (Vitamin B12) in 1099 subjects.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2002 (The journal of nutrition, health & aging), a journal based in France.

More context: the Cyanocobalamin (Vitamin B12) compound page, all human trials.